In this episode of The Onco'Zine Brief, Peter Hofland talks with David M. Cognetti, MD, a Professor and Chair in the Department Head and Neck Surgery at Thomas Jefferson University Hospital in Philadelphia.
Hofland and Cognetti talk about head and neck cancer and a novel treatment approach called Photoimmunotherapy.
According to the American Cancer Society, Head and neck cancer accounts for about 4% of all cancers in the United States. In the United States in 2023, an estimated 67,000 people will be diagnosed with head and neck cancer and about 15,000 patients are expected to die of the disease.
Today, many cancers of the head and neck can be cured, especially if they are found early. And while eliminating the cancer is the primary goal of treatment, preserving the function of the nearby nerves, organs, and tissues is also very important.
Photoimmunotherapy is a recently developed hybrid cancer therapy to treat diseases by linking specific antibodies with photosensitizers to form photoimmunoconjugates.
About The Onco'Zine Brief
The Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio.
For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, visit to https://lp.constantcontactpages.com/su/jj9JqsS/MediaKit202122/, visit https://www.patreon.com/theoncozinebrief at or https://www.oncozine.com/advertisement-sponsorship-options/.
For more information about cancer and cancer treatments, visit our online journal https://www.oncozine.com/
To sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866.
The Onco’Zine Brief is made possible, in part, by http://www.javaoriginalcoffee.com/ – the home of artisan roasted coffee and https://roastmasterz.com.
